^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    crolibulin (EPC2407)

    i
    Associations
    News

    Trials

    Company:
    Immune Pharma
    Drug class:
    Tubulin polymerization inhibitor, Vascular disrupting agent, Apoptosis inducer
    Related drugs:
    Associations
    News

    Trials

    Apply
    A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC) (NCT01240590)
    Phase 1/2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    04/10/2017
    Initiation :
    01/26/2011
    Primary completion :
    08/31/2015
    Completion :
    12/31/2016
    BRAF
    |
    cisplatin • crolibulin (EPC2407)